Drug-Induced Acute Liver Injury
5
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Bicyclol 25mg Tablet
Research Leaders
8 sponsors active, led by Beijing Union Pharmaceutical Factory Ltd
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
20%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.
Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.
The Multi-Center, Randomized, Double-blind, Positive Controlled Clinical Trial of Bicyclol in the Treatment of Acute DILI
The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI
Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose
Research Network
Common Treatments
- Bicyclol 25mg Tablet1
- Bicyclol Tablets1
- Polyene Phosphatidylcholine Capsules 228mg Particle1
- Polyene Phosphatidylcholine1
- Antituberculosis Drugs Group1
Active Sponsors
- Beijing Union Pharmaceutical Factory Ltd2
- Drug Induced Liver Disease Study Group2
- University of Aarhus1
- Savværksejer Jeppe Juhl og Hustru Ovita Juhls mindelegat1
- The Danish Council for Strategic Research1
Top Investigators
RenJi Hospital
Abeer Esmat Abd El-Hamed
905th Hospital of Pla Navy
Professor/Abeer Sharaf Eldin Abdel Rehim
Tianjin Medical University Cancer Institute and Hospital
Related Conditions
- Tuberculosis Tb1